Contact Person
David Munis Zepernick

Head of Business Development and Public Affairs

Phone: (M) +45 2498 1668


Below you will find the latest news from MVA. You can also sign up to our newsletter MVA Update.

MVA Update is an electronic newsletter providing you with news about MVA and an overview of our events and other relevant events in Medicon Valley. You can also check out our calendar for more information about life science events in the region.

If you have any questions regarding our news section or media inquiries then please contact David Munis Zepernick, Head of Press on +45 2498 1668.

21 Apr

MVA-member, Chr. Hansen, acquires HSO Health Care to grow probiotics offering for women’s health

Yesterday, MVA-member and MVA Microbiome Network co-founder, Chr. Hansen Holding A/S, and HSO Health Care GmbH today entered into an agreement, under which Chr. Hansen will acquire Austrian HSO Health Care. The acquisition of HSO Health Care GmbH cements Chr.

17 Apr

Prof. Thomas Arnebrant is the permanent representative of Malmö Universitet in the board of directors of the 300 member strong life science cluster organisation, Medicon Valley Alliance

Following MVA´s Ordinary General Meeting Thursday afternoon, today´s article in Øresund News, highlights the fact that prof. Thomas Arnebrant and Malmö University have now upgraded their involvement and engagement in the Swedish-Danish life science cluster and now share the same

17 Apr

Linn Mandahl, General Manager, AbbVie Scandinavia joins the Board of Directors of the growing DA-SE life science cluster organisation, Medicon Valley Alliance

At this year´s Medicon Valley Alliance Ordinary General Meeting, Thursday 16th of April, which was organized as an online meeting, the MVA Board of Directors had the pleasure of welcoming, Linn Mandahl, General Manager, AbbVie Scandinavia as a new board

15 Apr

Interview with CEO Immunitrack, Stephan Thorgrimsen about the fight against the Corona /COVID-19 virus

CSO, Sune Justesen, and CEO, Stephan Thorgrimsen, founders of Immunitrack Q1) Can you perhaps explain a little about the general vaccine development strategy adopted by most companies today? There is a need to develop fast an effective vaccine against Sars-CoV2.

14 Apr

3 Q&A to Richard E. Johnsson, Ph.D., Associate Professor, Head of Peptide Chemistry, Red Glead Discovery

MVA-members should use the opportunity to get to know each other better. Today, we asked, Richard E. Johnsson, Ph.D., Associate Professor, Head of Peptide Chemistry at MVA-member company, Red Glead Discovery, about their current involvement in the development of a

06 Apr

MVA-member, Symphogen, acquired by French Servier

According to a press release issued Friday 3rd of April, the acquisition, the result of a process that has been underway for several months now, will strengthen Servier’s antibody capabilities and ensure that Symphogen’s antibody discovery and early-development platform is

02 Apr

Four Medicon Valley based hospitals involved in Phase II clinical trial with promising COVID-19 candidate

The Austrian Biotech Company, APEIRON Biologics, has obtained regulatory approvals for the treatment of 200 COVID-19 patients in Austria, Germany and Denmark with APN01, which has the potential to block the infection of cells by the novel COVID-19 virus and

01 Apr

MVA-member, MSD, to deliver pneumoniae vaccine for all Danes +65

In order to reduce the number of particularly vulnerable patients  and thereby ensure sufficient healthcare capacity in the current Corona situation, the Danish Government and Parliament Tuesday night announced a new free pneumonia vaccine initiative for all Danes +65. The

31 Mar

Medicon Valley Alliance, MVA-members and MVA-partners figure prominently in the recently published Healthtech Magazine distributed with the financial daily Børsen

Medicon Valley Alliance, MVA-members such as Scandion Oncology Ledidi and 2CureX and a number of MVA-partners and friends figure prominently in the recently published Healthtech Magazine distributed with the financial daily Børsen. Apart from the interview with MVA New Year